Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy ...
Feb 6, 2013
0
0
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.
Dec 14, 2012
0
0
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) and The Ohio State University Wexner Medical Center are conducting ...
Jul 29, 2020
0
3
A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of ...
Jun 12, 2018
0
6
The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...
May 1, 2018
0
128
Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma (NHL) showed that survival at 4 years following allogeneic hematopoietic cell transplantation (HCT) for patients age 65 years and older is comparable ...
Feb 21, 2018
0
3
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since ...
May 2, 2016
0
2
Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous ...
Dec 7, 2015
0
0
Cancer drug maker Celgene said it will buy Receptos for $7.32 billion in cash, gaining a drug Receptos is studying as a treatment for multiple sclerosis and ulcerative colitis.
Jul 14, 2015
0
10
Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...
Nov 26, 2014
0
0
